Vivien H. C. Bramwell
Research Subjects
Vivien H. C. Bramwell has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ann F. Chambers
Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
3 shared publications Sylvia M. Wilson
London Regional Cancer Program
3 shared publicationsAlan B. Tuck
London Regional Cancer Program
2 shared publicationsAnna Tomiak
London Regional Cancer Program
2 shared publicationsFrancisco Perera
London Regional Cancer Program
2 shared publications- Gordon Stuart Doig
Northern Clinical School Intensive Care Research Unit, Sydney Medical School, University of Sydney, Sydney, Australia
2 shared publications
Latest Publications
- Open Access
- 23 July 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (2) , 283-290
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
Background: In the early 1990s, the role of adjuvant tamoxifen in premenopausal women with early breast cancer (EBC) was not established. Similarly, optimum timing relative to adjuvant chemotherapy and efficacy of tamoxifen in hormone receptor-negative tumors were unclear. Patients and methods: Premenopausal women with EBC, any hormone receptor status, after surgery received standard adjuvant chemotherapy [doxorubicin (adriamycin)/cyclophosphamide, cyclophosphamide/methotrexate/5-fluorouracil, or cyclophosphamide/epirubicin/5-fluorouracil] followed by randomization to tamoxifen or placebo for 5 years. Outcomes were overall survival (OS), disease-free survival (DFS), toxicity, and compliance with therapy. Results: Median follow-up for 672 women was 9.7 years. Multivariate analysis showed improved DFS [78.2% versus 71.3% at 5 years; hazard ratio (HR) 0.77; P = 0.056] and a trend for improved OS (86.6% versus 82.1% at 5 years; HR 0.78; P = 0.12). There was no evidence of greater benefit for the receptor-positive subgroup. Compliance with treatment was suboptimal in both arms, with 103 (31%) women on tamoxifen and 70 (21%) on placebo-stopping therapy early because of toxicity, refusal, or other choices. Conclusions: Adjuvant tamoxifen, given after chemotherapy to premenopausal women with EBC, improved 5-year DFS. Poor compliance may have reduced treatment efficacy.
- 23 July 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (2) , 283-290
Open AccessA randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
Background: In the early 1990s, the role of adjuvant tamoxifen in premenopausal women with early breast cancer (EBC) was not established. Similarly, optimum timing relative to adjuvant chemotherapy and efficacy of tamoxifen in hormone receptor-negative tumors were unclear. Patients and methods: Premenopausal women with EBC, any hormone receptor status, after surgery received standard adjuvant chemotherapy [doxorubicin (adriamycin)/cyclophosphamide, cyclophosphamide/methotrexate/5-fluorouracil, or cyclophosphamide/epirubicin/5-fluorouracil] followed by randomization to tamoxifen or placebo for 5 years. Outcomes were overall survival (OS), disease-free survival (DFS), toxicity, and compliance with therapy. Results: Median follow-up for 672 women was 9.7 years. Multivariate analysis showed improved DFS [78.2% versus 71.3% at 5 years; hazard ratio (HR) 0.77; P = 0.056] and a trend for improved OS (86.6% versus 82.1% at 5 years; HR 0.78; P = 0.12). There was no evidence of greater benefit for the receptor-positive subgroup. Compliance with treatment was suboptimal in both arms, with 103 (31%) women on tamoxifen and 70 (21%) on placebo-stopping therapy early because of toxicity, refusal, or other choices. Conclusions: Adjuvant tamoxifen, given after chemotherapy to premenopausal women with EBC, improved 5-year DFS. Poor compliance may have reduced treatment efficacy.
- 25 April 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 114 (3) , 503-511
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
Background Blood levels of the extracellular domain of HER-2/neu (ECD/HER2) have been suggested to have potential as a tumor marker in breast cancer. Our aim was to assess the prognostic value of baseline levels of ECD/HER2, but more importantly changes in levels over time, in women with metastatic breast cancer. Methods Baseline and serial levels of ECD/HER2 were measured in 158 women with newly-diagnosed metastatic breast cancer, in whom we previously performed serial measurement of plasma osteopontin. ECD/HER2 was measured in 1,282 serum samples using a validated ELISA at baseline and every 3–12 weeks during and after therapy until death (median, n = 8 samples per patient). Multivariate time-dependent survival analyses were conducted using models that right-censored patient outcomes 3, 6 and 12 months after last known ECD/HER2 measurement. Results Thirty-four patients (22%) had elevated baseline ECD/HER2 (median 10.2 ng/ml: range 4.1–40.4 ng/ml). In univariate analysis, elevated baseline ECD/HER2 was associated with short survival (P = 0.001). In a multivariate model incorporating standard clinical prognostic factors, baseline ECD/HER2 was significantly associated with survival duration (RR 1.029; P = 0.020). Presence of visceral metastases and ECOG status 2–4 also retained significance. In a multivariate model incorporating standard prognostic factors and changes in sequential ECD/HER2 levels, an ECD/HER2 increase of >12 ng/ml at any time was the variable with most prognostic value for poor survival (RR 6.10; P = 0.0003); poor ECOG status also retained significance. Conclusion Increases over time of ECD/HER2 levels were strongly associated with poor survival in this cohort of women with metastatic breast cancer.
- 25 April 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 114 (3) , 503-511
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
Background Blood levels of the extracellular domain of HER-2/neu (ECD/HER2) have been suggested to have potential as a tumor marker in breast cancer. Our aim was to assess the prognostic value of baseline levels of ECD/HER2, but more importantly changes in levels over time, in women with metastatic breast cancer. Methods Baseline and serial levels of ECD/HER2 were measured in 158 women with newly-diagnosed metastatic breast cancer, in whom we previously performed serial measurement of plasma osteopontin. ECD/HER2 was measured in 1,282 serum samples using a validated ELISA at baseline and every 3–12 weeks during and after therapy until death (median, n = 8 samples per patient). Multivariate time-dependent survival analyses were conducted using models that right-censored patient outcomes 3, 6 and 12 months after last known ECD/HER2 measurement. Results Thirty-four patients (22%) had elevated baseline ECD/HER2 (median 10.2 ng/ml: range 4.1–40.4 ng/ml). In univariate analysis, elevated baseline ECD/HER2 was associated with short survival (P = 0.001). In a multivariate model incorporating standard clinical prognostic factors, baseline ECD/HER2 was significantly associated with survival duration (RR 1.029; P = 0.020). Presence of visceral metastases and ECOG status 2–4 also retained significance. In a multivariate model incorporating standard prognostic factors and changes in sequential ECD/HER2 levels, an ECD/HER2 increase of >12 ng/ml at any time was the variable with most prognostic value for poor survival (RR 6.10; P = 0.0003); poor ECOG status also retained significance. Conclusion Increases over time of ECD/HER2 levels were strongly associated with poor survival in this cohort of women with metastatic breast cancer.
- 14 November 2006
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (4) , 1254-1256
Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma
- 14 November 2006
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 14 (4) , 1254-1256
Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma
- 1 June 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (11) , 3337-3343
Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer
Purpose: Osteopontin is a malignancy-associated protein measurable in blood and tumor tissue. To evaluate its prognostic value in advanced disease, we conducted a prospective clinical study measuring serial osteopontin plasma levels in women with metastatic breast cancer throughout the course of their disease. Experimental Design: One hundred fifty-eight women with newly diagnosed metastatic breast cancer were enrolled in the study. Plasma osteopontin was measured using our validated ELISA, at baseline and every 3 to 12 weeks during and after therapy until death. Multivariate time-dependent survival analyses were conducted using models that right censored patient outcomes 3, 6, and 12 months after the last known osteopontin measurement. Results: Osteopontin was measured in 1,378 samples (median, 9 per patient). Ninety-nine patients had elevated baseline osteopontin (median, 177 ng/mL; range, 1-2,648 ng/mL). In univariate analysis, elevated baseline osteopontin was associated with short survival (P = 0.02). In a multivariate model incorporating standard prognostic factors, baseline osteopontin was significantly associated with survival duration (relative risk, 1.001; P = 0.038). Metastasis-free interval, visceral metastases, and Eastern Cooperative Oncology Group status 2 to 4 also retained significance. In a multivariate model incorporating standard prognostic factors and changes in sequential osteopontin levels, an osteopontin increase of >250 ng/mL at any time was the variable with the most prognostic value for poor survival (relative risk, 3.26; P = 0.0003), and poor Eastern Cooperative Oncology Group status also retained significance. Conclusions: This is the first study to show that in women with metastatic breast cancer, increases in osteopontin levels over time are strongly associated with poor survival. Sequential monitoring of osteopontin may have use in making treatment decisions for these patients.
- 1 June 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (11) , 3337-3343
Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer
Purpose: Osteopontin is a malignancy-associated protein measurable in blood and tumor tissue. To evaluate its prognostic value in advanced disease, we conducted a prospective clinical study measuring serial osteopontin plasma levels in women with metastatic breast cancer throughout the course of their disease. Experimental Design: One hundred fifty-eight women with newly diagnosed metastatic breast cancer were enrolled in the study. Plasma osteopontin was measured using our validated ELISA, at baseline and every 3 to 12 weeks during and after therapy until death. Multivariate time-dependent survival analyses were conducted using models that right censored patient outcomes 3, 6, and 12 months after the last known osteopontin measurement. Results: Osteopontin was measured in 1,378 samples (median, 9 per patient). Ninety-nine patients had elevated baseline osteopontin (median, 177 ng/mL; range, 1-2,648 ng/mL). In univariate analysis, elevated baseline osteopontin was associated with short survival (P = 0.02). In a multivariate model incorporating standard prognostic factors, baseline osteopontin was significantly associated with survival duration (relative risk, 1.001; P = 0.038). Metastasis-free interval, visceral metastases, and Eastern Cooperative Oncology Group status 2 to 4 also retained significance. In a multivariate model incorporating standard prognostic factors and changes in sequential osteopontin levels, an osteopontin increase of >250 ng/mL at any time was the variable with the most prognostic value for poor survival (relative risk, 3.26; P = 0.0003), and poor Eastern Cooperative Oncology Group status also retained significance. Conclusions: This is the first study to show that in women with metastatic breast cancer, increases in osteopontin levels over time are strongly associated with poor survival. Sequential monitoring of osteopontin may have use in making treatment decisions for these patients.
- Open Access
- 1 December 2005
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 4 (12) , 1336-1341
Expression of osteopontin and HGF/Met in adult soft tissue tumors
There is a need for molecular markers that predict biological behavior of adult soft tissue tumors. Elevated levels of osteopontin (OPN) a transformation-linked protein, have been associated with poor survival in many cancers. OPN induces cell migration in cancer cells, in part through activation of the hepatocyte growth factor (HGF) receptor (Met) and its signaling pathway. Met expression has been associated with a poor prognosis in some sarcomas. In a series of 15 patients with adult soft tissue tumors, we found that mRNA levels of OPN (p=0.015), Met (p=0.03) and HGF (p<0.001) were significantly higher in tumor tissues relative to paired normal tissues. By immunohistochemistry, in tumor tissue from 33 patients, we demonstrated that increased expression of OPN, but not Met protein, was associated with higher stage (p=0.025) and grade (p=0.005). We found that increased expression of OPN, but not Met protein, was associated with decreased overall survival (p=0.008) at five years. This study, which is the first to examine coexpression of these two markers, suggests that OPN may have potential as a prognostic marker in adult soft tissue sarcomas, and further that OPN+/-Met signaling pathways may contribute to their biological behavior.
- 1 December 2005
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 4 (12) , 1336-1341
Open AccessExpression of osteopontin and HGF/Met in adult soft tissue tumors
There is a need for molecular markers that predict biological behavior of adult soft tissue tumors. Elevated levels of osteopontin (OPN) a transformation-linked protein, have been associated with poor survival in many cancers. OPN induces cell migration in cancer cells, in part through activation of the hepatocyte growth factor (HGF) receptor (Met) and its signaling pathway. Met expression has been associated with a poor prognosis in some sarcomas. In a series of 15 patients with adult soft tissue tumors, we found that mRNA levels of OPN (p=0.015), Met (p=0.03) and HGF (p<0.001) were significantly higher in tumor tissues relative to paired normal tissues. By immunohistochemistry, in tumor tissue from 33 patients, we demonstrated that increased expression of OPN, but not Met protein, was associated with higher stage (p=0.025) and grade (p=0.005). We found that increased expression of OPN, but not Met protein, was associated with decreased overall survival (p=0.008) at five years. This study, which is the first to examine coexpression of these two markers, suggests that OPN may have potential as a prognostic marker in adult soft tissue sarcomas, and further that OPN+/-Met signaling pathways may contribute to their biological behavior.
- 21 July 2003
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (1) , CD003293
Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma
Considerable controversy exists as to whether any benefit of doxorubicin-based combination chemotherapy outweighs increased toxic effects, inconvenience, and additional costs, compared to single-agent doxorubicin. There is substantial variation in clinical practice in the treatment of patients with locally advanced and metastatic soft tissue sarcoma (STS). To determine: 1) the effect, if any on response rate or survival, by using doxorubicin-based combination chemotherapy compared with single-agent doxorubicin for the treatment of patients with incurable locally advanced or metastatic STS 2)if combination chemotherapy is associated with increased adverse effects compared with single-agent doxorubicin in this setting. We searched CENTRAL (Cochrane Library, issue 4, 2002), MEDLINE (1966 to October 2002), CANCER LIT (1975 to October 2002), reference lists, the Physician Data Query (PDQ) clinical trials database, and the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (1995 to 2002). Randomized controlled trials (RCTs) comparing single-agent doxorubicin with doxorubicin-based combination chemotherapy in adults with locally advanced or metastatic STS requiring palliative chemotherapy. Abstracts and full reports published in English were eligible. Data were abstracted and assessed by two reviewers. Response and survival data were pooled. Data on adverse effects was tabulated. Data on 2281 participants from eight RCTs were available from reports of single-agent doxorubicin versus doxorubicin-based combination chemotherapy. Meta-analysis using the fixed effect model detected a higher tumour response rate with combination chemotherapy compared with single-agent chemotherapy (odds ratio [OR= 1.29; 95% confidence interval [CI], 1.03 to 1.60; p = 0.03), but the OR from a pooled analysis using the random effects model and the same data did not achieve statistical significance (OR= 1.26; 95% CI, 0.96 to 1.67; p = 0.10). No significant difference between the two regimens was detected in the pooled one-year mortality rate (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14) or two-year mortality rate (OR = 0.84; 95% CI, 0.67 to 1.06; p=0.13) (N=2097). Although reporting of adverse effects was limited and inconsistent among trials (making pooling of data for this outcome impossible), adverse effects such as nausea/vomiting and hematologic toxic effects were consistently reported as being worse with combination chemotherapy across the eight eligible studies. Compared to single-agent doxorubicin, the combination chemotherapy regimens evaluated, given in conventional doses, produced only marginal increases in response rates, at the expense of increased toxic effects and with no improvements in overall survival. Quimioterapia basada en doxorrubicina para el tratamiento paliativo de pacientes adultos con sarcoma de partes blandas localmente avanzado o metastásico Existe una considerable controversia acerca de si cualquier beneficio de la quimioterapia de combinación basada en doxorrubicina supera el aumento de efectos tóxicos, la inconveniencia y los costos adicionales, en comparación con la doxorrubicina como agente único. Existe una variación apreciable en la práctica clínica en cuanto al tratamiento de pacientes con sarcoma de tejidos blandos localmente avanzado y metastásico (STB). Determinar: 1) el efecto, si existe alguno, sobre la tasa de respuesta o la supervivencia al utilizar quimioterapia de combinación basada en doxorrubicina en comparación con la doxorrubicina como agente único para el tratamiento de pacientes con STB localmente avanzado o metastásico incurable 2) si la quimioterapia de combinación se halla relacionada con un aumento de los efectos adversos, en comparación con la doxorrubicina como agente único en este ámbito. Se realizaron búsquedas en CENTRAL (la Cochrane Library, número 4, 2002), MEDLINE (1966 a octubre de 2002), CANCER LIT (1975 a octubre de 2002), las listas de referencias, la base de datos de ensayos clínicos del Physician Data Query (PDQ) y en las actas de reuniones anuales de la American Society of Clinical Oncology (ASCO) (1995 a 2002). Ensayos controlados aleatorios (ECA) que compararon la quimioterapia con doxorrubicina como agente único con la quimioterapia de combinación basada en doxorrubicina en adultos con STB localmente avanzado o metastásico que requirieron quimioterapia paliativa. Los resúmenes e informes completos publicados en inglés fueron elegibles. Los datos fueron resumidos y evaluados independientemente por dos revisores. Se combinaron los datos de respuesta y supervivencia. Se tabularon los datos sobre los efectos adversos. Los datos sobre 2281 participantes de ocho ECA se obtuvieron a partir de informes de la quimioterapia con doxorrubicina como agente único versus quimioterapia de combinación basada en doxorrubicina. El metanálisis con el modelo de efectos fijos detectó una tasa de respuesta tumoral mayor con la quimioterapia de combinación en comparación con la quimioterapia con agente único (odds-ratio [OR = 1,29; intervalo de confianza [IC] del 95%: 1,03 a 1,60; p = 0,03), pero el OR de un análisis combinado con el modelo de efectos aleatorios y los mismos datos no alcanzó una significación estadística (OR = 1,26; IC del 95%: 0,96 a 1,67; p = 0,10). No se detectaron diferencias significativas entre los dos regímenes en la tasa de mortalidad combinada al año (OR = 0,87; IC del 95%: 0,73 a 1,05; p = 0,14) o la tasa de mortalidad a dos años (OR = 0,84; IC del 95%: 0,67 a 1,06; p = 0,13) (N = 2097). Aunque la información sobre los efectos adversos fue limitada e inconsistente entre los ensayos (lo que imposibilitó la combinación de los datos para este resultado) se informó de manera consistente que los efectos adversos como las náuseas / vómitos y los efectos tóxicos hematológicos fueron peores con la quimioterapia de combinación entre los ocho estudios elegibles. En comparación...
- 21 July 2003
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (1) , CD003293
Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma
Considerable controversy exists as to whether any benefit of doxorubicin-based combination chemotherapy outweighs increased toxic effects, inconvenience, and additional costs, compared to single-agent doxorubicin. There is substantial variation in clinical practice in the treatment of patients with locally advanced and metastatic soft tissue sarcoma (STS). To determine: 1) the effect, if any on response rate or survival, by using doxorubicin-based combination chemotherapy compared with single-agent doxorubicin for the treatment of patients with incurable locally advanced or metastatic STS 2)if combination chemotherapy is associated with increased adverse effects compared with single-agent doxorubicin in this setting. We searched CENTRAL (Cochrane Library, issue 4, 2002), MEDLINE (1966 to October 2002), CANCER LIT (1975 to October 2002), reference lists, the Physician Data Query (PDQ) clinical trials database, and the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (1995 to 2002). Randomized controlled trials (RCTs) comparing single-agent doxorubicin with doxorubicin-based combination chemotherapy in adults with locally advanced or metastatic STS requiring palliative chemotherapy. Abstracts and full reports published in English were eligible. Data were abstracted and assessed by two reviewers. Response and survival data were pooled. Data on adverse effects was tabulated. Data on 2281 participants from eight RCTs were available from reports of single-agent doxorubicin versus doxorubicin-based combination chemotherapy. Meta-analysis using the fixed effect model detected a higher tumour response rate with combination chemotherapy compared with single-agent chemotherapy (odds ratio [OR= 1.29; 95% confidence interval [CI], 1.03 to 1.60; p = 0.03), but the OR from a pooled analysis using the random effects model and the same data did not achieve statistical significance (OR= 1.26; 95% CI, 0.96 to 1.67; p = 0.10). No significant difference between the two regimens was detected in the pooled one-year mortality rate (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14) or two-year mortality rate (OR = 0.84; 95% CI, 0.67 to 1.06; p=0.13) (N=2097). Although reporting of adverse effects was limited and inconsistent among trials (making pooling of data for this outcome impossible), adverse effects such as nausea/vomiting and hematologic toxic effects were consistently reported as being worse with combination chemotherapy across the eight eligible studies. Compared to single-agent doxorubicin, the combination chemotherapy regimens evaluated, given in conventional doses, produced only marginal increases in response rates, at the expense of increased toxic effects and with no improvements in overall survival. Quimioterapia basada en doxorrubicina para el tratamiento paliativo de pacientes adultos con sarcoma de partes blandas localmente avanzado o metastásico Existe una considerable controversia acerca de si cualquier beneficio de la quimioterapia de combinación basada en doxorrubicina supera el aumento de efectos tóxicos, la inconveniencia y los costos adicionales, en comparación con la doxorrubicina como agente único. Existe una variación apreciable en la práctica clínica en cuanto al tratamiento de pacientes con sarcoma de tejidos blandos localmente avanzado y metastásico (STB). Determinar: 1) el efecto, si existe alguno, sobre la tasa de respuesta o la supervivencia al utilizar quimioterapia de combinación basada en doxorrubicina en comparación con la doxorrubicina como agente único para el tratamiento de pacientes con STB localmente avanzado o metastásico incurable 2) si la quimioterapia de combinación se halla relacionada con un aumento de los efectos adversos, en comparación con la doxorrubicina como agente único en este ámbito. Se realizaron búsquedas en CENTRAL (la Cochrane Library, número 4, 2002), MEDLINE (1966 a octubre de 2002), CANCER LIT (1975 a octubre de 2002), las listas de referencias, la base de datos de ensayos clínicos del Physician Data Query (PDQ) y en las actas de reuniones anuales de la American Society of Clinical Oncology (ASCO) (1995 a 2002). Ensayos controlados aleatorios (ECA) que compararon la quimioterapia con doxorrubicina como agente único con la quimioterapia de combinación basada en doxorrubicina en adultos con STB localmente avanzado o metastásico que requirieron quimioterapia paliativa. Los resúmenes e informes completos publicados en inglés fueron elegibles. Los datos fueron resumidos y evaluados independientemente por dos revisores. Se combinaron los datos de respuesta y supervivencia. Se tabularon los datos sobre los efectos adversos. Los datos sobre 2281 participantes de ocho ECA se obtuvieron a partir de informes de la quimioterapia con doxorrubicina como agente único versus quimioterapia de combinación basada en doxorrubicina. El metanálisis con el modelo de efectos fijos detectó una tasa de respuesta tumoral mayor con la quimioterapia de combinación en comparación con la quimioterapia con agente único (odds-ratio [OR = 1,29; intervalo de confianza [IC] del 95%: 1,03 a 1,60; p = 0,03), pero el OR de un análisis combinado con el modelo de efectos aleatorios y los mismos datos no alcanzó una significación estadística (OR = 1,26; IC del 95%: 0,96 a 1,67; p = 0,10). No se detectaron diferencias significativas entre los dos regímenes en la tasa de mortalidad combinada al año (OR = 0,87; IC del 95%: 0,73 a 1,05; p = 0,14) o la tasa de mortalidad a dos años (OR = 0,84; IC del 95%: 0,67 a 1,06; p = 0,13) (N = 2097). Aunque la información sobre los efectos adversos fue limitada e inconsistente entre los ensayos (lo que imposibilitó la combinación de los datos para este resultado) se informó de manera consistente que los efectos adversos como las náuseas / vómitos y los efectos tóxicos hematológicos fueron peores con la quimioterapia de combinación entre los ocho estudios elegibles. En comparación...
- Open Access
Management of Advanced Adult Soft Tissue Sarcoma
- 1 December 1995
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 41 (5) , 271-279
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets
- 1 December 1995
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 41 (5) , 271-279
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets